Introduction {#sec1}
============

The transcription factor *Nanog* was identified based on its ability to support embryonic stem cell (ESC) self-renewal in the absence of leukemia inhibitory factor (LIF) ([@bib2]). Further studies demonstrated that *Nanog* helps to maintain pluripotency in ESCs by promoting *Oct4* and *Sox2* expression, while inhibiting a gene expression program leading to primitive endoderm differentiation ([@bib15]). *Nanog* levels have been shown to fluctuate greatly within ESC cultures ([@bib3; @bib13]). It has been proposed that allelic regulation of the *Nanog* gene could contribute to its heterogeneous expression pattern ([@bib13; @bib3; @bib20; @bib10; @bib11; @bib14]). However, more recent single-cell studies using single-molecule mRNA fluorescence in situ hybridization or allelic reporters suggest that allelic regulation of *Nanog* may not strongly contribute to variable *Nanog* expression ([@bib5; @bib7]).

Although the mechanisms that regulate the expression of *Nanog* continue to be intensively studied, it has been shown that both alleles of *Nanog* can be eliminated in ESCs without interfering with their differentiation capacity or somatic engraftment in chimeric animals after blastocyst injection ([@bib3]). Thus, although *Nanog* may help to maintain pluripotency, it is not strictly required.

Subsequent reports argued that although *Nanog* is not essential for ESC maintenance, it is absolutely necessary for the establishment of new ESC lines from blastocyst-stage embryos ([@bib19]). Similarly, it was found that induced pluripotent stem cell (iPSC) lines could not be derived from *Nanog*^−/−^ somatic cells ([@bib19]). These observations led to the conclusion that *Nanog* is an essential "gate keeper," which must be expressed before a cell can transit to a pluripotent "ground state."

Given the important role of *Nanog* in the maintenance of pluripotency, it is perhaps surprising that addition of *Nanog* to iPSC-reprogramming cocktails does not necessarily increase the efficiency of reprogramming ([@bib22]). Moreover, it has been shown that several distinct combinations of transcription factors can reprogram fibroblasts into iPSCs ([@bib1]) and that the *Nanog* target gene *Esrrb* can compensate for *Nanog* deficiency in some contexts ([@bib6; @bib12]). Finally, single-cell analysis of the reprogramming process suggests that it occurs through a stochastic series of events in which transcription factor binding and downstream transcriptional cascades can occur at random ([@bib1; @bib16]). Consistent with the mounting evidence that there are many independent pathways to pluripotency, we report here that although eliminating *Nanog* decreases the efficiency of reprogramming, *Nanog* is not required for the generation of iPSCs, even under canonical conditions utilizing the expression of *Klf4*, *Sox2*, *Oct4*, and *cMyc* (KSOM).

Results {#sec2}
=======

We previously found that greatly increasing the titer and promoter strength of retroviral elements encoding reprogramming factors can dramatically improve the efficiency of iPSC generation ([@bib4; @bib9]). We reasoned that the relatively high efficiency enabled by these modifications might provide a larger window of opportunity than that available in earlier experiments ([@bib19]) for determining whether *Nanog* was truly necessary for the establishment of pluripotency.

In order to test this hypothesis, we first derived *Nanog*^*−/−*^ somatic cells to use as a target population for reprogramming experiments. We utilized *Nanog^−/−^* ESCs engineered to express GFP under the control of the ubiquitously expressed CAGGS promoter through random integration of the CAGGS::GFP transgene. These cells were injected into embryonic day 3.5 (E3.5) blastocysts, transfered into recipient females, and resulting embryos were allowed to develop to E1.5 ([@bib3]). We then prepared mouse embryonic fibroblasts (MEFs) from the resulting chimeric embryos and purified *Nanog*^*−/−*^ MEFs via FACS based on their expression of GFP ([Figure S1](#app3){ref-type="sec"} available online).

As a component of the gene-targeting strategy used to delete *Nanog*, a neomycin-resistance gene was placed under control of its endogenous promoter ([@bib3]). Thus, selection with the neomycin analog G418 could be used to rule out the unlikely possibility that undifferentiated pluripotent cells, capable of activating the *Nanog* promoter, were present in our *Nanog*^−/−^ MEF cultures. We found that no cells in our MEF preparations survived G418 selection. Thus, there were no undifferentiated cells remaining in these MEF cultures, and we concluded that they were an appropriate substrate for determining whether *Nanog* was indeed required for the establishment of pluripotency ([Figure 1](#fig1){ref-type="fig"}D, top panel).

To ask whether *Nanog*^*−/−*^ MEFs could be reprogrammed, we transduced them with high-titer retroviruses encoding either *Klf4*, *Sox2*, and *Oct4* (KSO) or KSOM ([Figure S1](#app3){ref-type="sec"}). After 21 days, we reproducibly observed an average of five colonies with an iPSC morphology per 180,000 *Nanog*^*−*/*−*^ MEFs transduced with KSOM, representing a reprogramming efficiency 100-fold lower than obtained using control *Nanog*^*+/+*^ MEFs ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S2](#app3){ref-type="sec"}B). The oncogene c-*Myc* is dispensable for reprogramming, and iPSCs generated in its absence are less tumorigenic in vivo. We therefore next sought to reprogram Nanog^−/−^ MEFs using only KSO. We reproducibly observed two to three putative iPSC colonies emerge per 180,000 MEFS using these three factors. Although the efficiency of apparent reprogramming was lower without *c-Myc*, we were able to generate iPSC lines using either KSO or KSOM ([Figure 1](#fig1){ref-type="fig"}A).

To test whether these *Nanog*^−/−^ cells were indeed reprogrammed, we isolated GFP^+^, putative iPSC colonies and expanded them in 2i media ([@bib18]). We designated two putative KSOM Nanog^−/−^ iPSC lines, G2 and G5, whereas two KSO iPSC lines were dubbed 3.1 and 3.2 ([Figure 1](#fig1){ref-type="fig"}C). These putative iPSCs maintained an ESC-like morphology over more than ten passages on both gelatin and irradiated feeders ([Figure 1](#fig1){ref-type="fig"}C). Like *Nanog*^−/−^ ESCs, they grow more slowly than control *Nanog*^*+/+*^ ESCs ([Figure 1](#fig1){ref-type="fig"}C).

Consistent with the notion that these putative *Nanog*^−/−^ iPSCs had been fully reprogrammed to ground state pluripotency, we found that they had silenced viral reprogramming transgenes and induced endogenous KSO expression ([Figures S2](#app3){ref-type="sec"} and [2](#fig2){ref-type="fig"}A). Endogenous *Oct4* was expressed in these putative *Nanog*^−/−^ iPSCs at levels similar to both control *Nanog*^*+/+*^ *ES*Cs and iPSCs as well as *Nanog*^*−/−*^ ESCs. *Sox2* and *Klf4* were expressed in putative *Nanog*^−/−^ iPSCs at levels similar to *Nanog*^*−/−*^ ESCs but slightly lower than control *Nanog*^*+/+*^ ESCs and iPSCs ([Figure 2](#fig2){ref-type="fig"}A).

To ask if the endogenous pluripotency network was activated in these putative *Nanog*^−/−^ iPSCs, we performed drug selection with G418. As mentioned above, because *Nanog*^−/−^ cells express the neomycin-resistance gene under control of the *Nanog* promoter, G418 can be used as a proxy for *Nanog* promoter activity ([@bib3]). After 4 days of G418 treatment, putative *Nanog*^−/−^ iPSC lines G2 and G5 grew without disturbance, whereas control V6.5 ESCs were drug sensitive ([Figure 1](#fig1){ref-type="fig"}D).

We next proceeded to further characterize gene expression in putative *Nanog*^−/−^ iPSCs. As expected, putative *Nanog*^*−/*−^ iPSCs did not express exon 2--4 of the *Nanog* transcript, consistent with the gene-targeting strategy used to generate the knockout line ([@bib3]). Conversely, high expression of *Nanog* was detected in control *Nanog*^*+/+*^ ESCs and iPSCs, but not in partially reprogrammed iPSCs (piPS B1) ([Figures 2](#fig2){ref-type="fig"}B and [S3](#app3){ref-type="sec"}). Convergent expression of *Utf1*, *Dppa2*, *Lin28*, and *Esrrb* has been demonstrated to be a stringent indicator of the pluripotent state ([@bib1]). Thus, we measured expression of *Utf1*, *Lin28*, *and Esrrb* in putative *Nanog*^−/−^ iPSC lines G2 and G5 and found that they were expressed at levels similar to those found in *Nanog*^−/−^ ESCs and control *Nanog*^+/+^ V6.5 ESCs. On the other hand, a partially reprogrammed *Nanog*^+/+^ cell line (piPS B1), which is composed of cells that are not pluripotent, did not express these genes ([Figure 2](#fig2){ref-type="fig"}B).

Having confirmed that the *Nanog*^−/−^ iPSCs expressed key markers of pluripotency, we sought to determine the extent to which the global expression profile of *Nanog*^−/−^ iPSCs recapitulated that of ESCs. To this end, we performed RNA sequencing (RNA-seq) of two replicates each of control *Nanog*^+/+^ ESC, iPSC, MEFs, and partially reprogrammed iPSC as well as *Nanog*^−/−^ ESC and two iPSC clones, G2 and G5. We observed RNA-seq reads aligning to *Nanog* exon1, but not exons 2--4, in both the *Nanog*^−/−^ ESC and iPSC clones ([Figure S3](#app3){ref-type="sec"}). This confirms the absence of Nanog expression and indicates that the endogenous *Nanog* promoter is activated in these cells. As expected, we observed many RNA-seq reads mapping to all exons in control *Nanog*^+/+^ ESCs and iPSCs, but not in control MEFs or partially reprogrammed iPSCs ([Figure S3](#app3){ref-type="sec"}).

Unsupervised hierarchical clustering of the samples based on the expression of all genes revealed that all pluripotent cells clustered together and apart from both MEFs and partially reprogrammed iPSCs. As expected, both *Nanog*^−/−^ iPSC lines showed a high degree of similarity to *Nanog*^−/−^ ESCs ([Figure 3](#fig3){ref-type="fig"}A). Pairwise comparisons further revealed that relative to MEFs, *Nanog*^−/−^ iPSCs were as similar to *Nanog*^−/−^ ESCs as control, Nanog^+/+^ iPSCs were to control Nanog^+/+^ ESCs ([Figure 3](#fig3){ref-type="fig"}C).

Analysis of a wide range of reported pluripotency markers revealed that *Nanog*^−/−^ iPSCs expressed all markers with a high degree of similarity to both *Nanog*^−/−^ ESCs and control ESCs and iPSCs ([Figure 3](#fig3){ref-type="fig"}B). Moreover, *Nanog*^−/−^ iPSCs expressed low levels of ectoderm, mesoderm, and fibroblast markers similar to *Nanog*^−/−^ ESCs. Interestingly, as previously reported in *Nanog*^−/−^ ESCs ([@bib3; @bib15]), each of the *Nanog*^−/−^ iPSC lines expressed increased levels of early endoderm markers including Sox17, Gata4, and Gata6 when compared to *Nanog*^+/+^ ESCs or *Nanog*^+/+^ iPSCs.

Finally, to definitively test whether these putative *Nanog*^−/−^ iPSCs were indeed pluripotent, we asked whether they could colonize chimeric embryos and contribute differentiated progeny to the three embryonic germ layers. We injected cells from putative *Nanog*^−/−^ iPSC lines G5, 3.1, and 3.2 into blastocysts and found that they contributed to E12.5 embryos by green fluorescence and to resulting chimeric adults by green fluorescence and coat color ([Figures 4](#fig4){ref-type="fig"}A--4C). In the case of the *Nanog*^−/−^ iPSC lines reprogrammed with KSO, 12 out of 16 and 3 out of 8 embryos recovered were chimeric, and for the *Nanog*^−/−^ iPSC line made with KSOM (G5), 3 out of 14 embryos were chimeric. Coat-color analysis of adult mice revealed that for the KSO *Nanog*^−/−^ iPSC lines, 8 out of 15 and 8 out of 14 animals were chimeric, and for the KSOM *Nanog*^−/−^, 3 out of 14 animals were chimeric. Importantly, *Nanog*^−/−^ cells contributed substantially to tissues from the three germ layers in adult chimeras, including the brain, heart, lung, and liver ([Figures 4](#fig4){ref-type="fig"}A and [S4](#app3){ref-type="sec"}A).

To evaluate if the Nanog^−/−^ iPSCs could contribute to the germline and generate mature germ cells, we crossed chimeric Nanog^−/−^ GFP^+^ iPSC males with C57BL/6 females. Genotyping for the GFP transgene in the resulting adult progeny revealed 7 out of 22 positive animals ([Figure 4](#fig4){ref-type="fig"}E). The genotyping strategy was further confirmed by detection of GFP expression in the tissues of transgene-positive animals, for example, F1 \#4, but not their transgene-negative littermates (F1 \#3, [Figure 4](#fig4){ref-type="fig"}F). Partially reprogrammed cells (piPS B1), on the other hand, did not contribute to embryonic or adult chimeras ([Figure 4](#fig4){ref-type="fig"}D). These experiments confirmed that unlike the partially reprogrammed *Nanog*^−/−^ cell lines previously derived ([@bib19]), the *Nanog*^−/−^ iPSC lines we report here were pluripotent and fully reprogrammed.

Discussion {#sec3}
==========

Although our results seem to contradict previous reports ([@bib19]), we believe that these incongruences are likely explained by a higher efficiency of reprogramming in our hands, which allowed us to observe relatively rare *Nanog*-independent reprogramming events that were previously undetected. Regardless, our findings underscore the redundant and pliable nature of reprogramming in vitro, further confirming that there are distinct routes to a pluripotent state. One the one hand, this is not surprising in light of recent studies showing that redundant factors within the pluripotency transcriptional network can compensate for loss of *Nanog*, and lineage-specific transcription factors can replace all canonical reprogramming factors when expressed in the right combinations ([@bib6; @bib12; @bib17]). On the other hand, recent reports that *Nanog* expression within pluripotent stem cell cultures is not as heterogeneous as previously believed make the finding that it is not required for transition to or maintenance in the pluripotent state surprising ([@bib5; @bib7]).

Similar to our observation that *Nanog*^−/−^ iPSCs could give rise to chimeric animals, *Nanog* null ESCs have been shown to contribute to the three germ layers ([@bib3]). However, in the case of ESC chimeras, *Nanog*^−/−^ GFP^+^ cells were not detected in the germline after E12.5. Because the CAGs::GFP construct that marks *Nanog*^−/−^ cells was introduced by random integration into ESCs, we reasoned that perhaps the GFP transgene might, by chance, not be expressed in cells of the germline that could hamper the ability to detect germline contribution of these cells. We therefore performed crosses using chimeras produced from *Nanog* null iPSCs and found that they could produce offspring carrying the GFP^+^ transgene originating from the injected iPSCs. Thus, these results indicate, in contrast to previous results, that Nanog^−/−^ iPSCs can give rise to functional, mature germ cells.

Here, we provide global transcriptional analysis of both our *Nanog*^*−/−*^ iPSCs as well as *Nanog*^−/−^ mESCs ([Figure 3](#fig3){ref-type="fig"}). Although these cells have been shown to robustly colonize chimeric embryos, we show that there are still many differences in global expression profiles between *Nanog*-deficient and wild-type (WT) pluripotent stem cells ([Figure 3](#fig3){ref-type="fig"}) ([@bib3]). A number of genes are differentially expressed between pluripotent cells of these two genotypes, and thus, it would be interesting to further investigate both the mechanism of activation of the core pluripotency network as well as the transcriptional circuit involved in pluripotency maintenance in this context.

Although we have done this work exclusively in murine cells, interactions between members of the core pluripotency network are highly conserved between mouse and human. While the relative inefficiency of iPSC reprogramming in human cells may make rare reprogramming events difficult to detect, it is of great interest to perform similar experiments in human cells. These studies may provide insights between the so-called naive and primed ESC states in the *NANOG*-deficient context ([@bib8]).

Based on our results, we conclude that although reprogramming is indeed less efficient in the absence of *Nanog*, *Nanog* is not required for the establishment of a pluripotent state, as has been previously suggested. Instead, we conclude that even under standard conditions, there are *Nanog*-independent routes to pluripotency.

Experimental Procedures {#sec4}
=======================

iPSC Generation {#sec4.1}
---------------

Parental *Nanog*^−/−^ mESCs were obtained from I. Chambers and were cultured on feeders in 2i plus LIF conditions as previously described by [@bib3] and [@bib18]. To obtain *Nanog*^−/−^ MEFs, *Nanog*^−/−^ mESCs were injected into blastocyst-stage embryos. At E12.5, MEFs were dissected out and sorted for constitutive GFP expression, indicating *Nanog*^−/−^ genotype ([@bib3]). For reprogramming, MEFs were transduced with retroviruses carrying murine KSO, with or without *c-Myc* exactly as described by [@bib9]. On day 20 posttransduction with reprogramming transgenes, iPSC colonies were picked and passaged onto feeders and cultured in 2i plus LIF conditions with passaging every 5 days ([@bib18]).

Chimera Generation {#sec4.2}
------------------

All procedures involving animal subjects were approved in advance by the Harvard University Institutional Animal Care and Use Committee. Chimeras were generated by injection of *Nanog*^−/−^ iPSCs into E3.5 strain 129 blastocysts. At E12.5, embryos were dissected, and whole embryos were analyzed for GFP expression in somatic tissues. Fourteen-day-old pups were dissected to analyze chimeric contribution in adult tissues by fluorescence. To analyze the contribution of *Nanog*^−/−^ iPSCs to the germline, adult male chimera animals were bred with C57BL/6 females, and resulting pups were genotyped with Jackson Laboratory GFP primers 5′-AGTTCATCTGCACCACCG-3′ and 5′- TCCTTGAAGAAGATGGTGCG-3′. Three-month-old adult progeny were analyzed for chimeric contribution to adult tissues.

qPCR {#sec4.3}
----

qPCR was performed using iScript cDNA Synthesis Kit and SYBR Green qPCR Supermix (Bio-Rad) according to manufacturers' instructions on a Bio-Rad iQ5. Levels were normalized to GAPDH expression using the delta-delta C~T~ method and plotted relative to expression in control V6.5 mESCs. Primer sequences used for qPCR: *Esrrb*, forward 5′-CACCTGCTAAAAAGCCATTGACT-3′, reverse 5′-CAACCCCTAGTAGATTCGAGACGAT-3′; *GAPDH*, forward 5′-TTCACCACCATGGAGAAGGC-3′, reverse 5′-CCCTTTTGGCTCCACCCT-3′; *Klf4*, forward 5′-CTATGCAGGCTGTGGCAAAACC-3′, reverse 5′-TTGCGGTAGTGCCTGGTCAGTT-3′; *Lin28*, forward 5′-GAAGAACATGCAGAAGCGAAGA-3′, reverse 5′-CCGCAGTTGTAGCACCTGTCT-3′; *Nanog*, forward 5′-AAACCAGTGGTTGAAGACTAGCAA-3′, reverse 5′-GGTGCTGAGCCCTTCTGAATC-3′; *Utf1*, forward 5′-GTCCCTCTCCGCGTTAGC-3′, reverse 5′-GGCAGGTTCGTCATTTTCC-3′; *Sox2*, forward 5′-AAGGGTTCTTGCTGGGTTTT-3′, reverse 5′-AGACCACGAAAACGGTCTTG-3′; *Oct4,* forward 5′-CACGAGTGGAAAGCAACTCA-3′, reverse 5′-AGATGGTGGTCTGGCTGAAC-3′.

RNA-Seq {#sec4.4}
-------

RNA was harvested from at least two biological replicates using TRIzol (Invitrogen) according to the manufacturers' directions. RNA quality was determined using BioAnalyzer (Aligent). RNA integrity numbers above 7.5 were deemed sufficiently high quality to proceed with library preparation. In brief, RNA-seq libraries were generated from ∼250 ng total RNA using the Illumina TruSeq RNA kit v.2, according to the manufacturers' directions. Libraries were sequenced at the Broad Institute's Genomics Platform on a HiSeq 2500. A total of 20--60 million 100 bp, paired end reads were obtained for each sample. Reference files of the murine genome build mm10, as well as Ensembl transcript annotations, were obtained from iGenomes (<http://support.illumina.com/sequencing/sequencing_software/igenome.ilmn>). Reads were aligned to the genome using the split read aligner TopHat (v.2.0.7) and Bowtie2 (v.2.0.5) using default parameters as previously described by [@bib21]. Transcript assembly, isoform-specific quantitation and differential expression analysis was performed using Cufflinks (v.2.1.1) ([@bib21]). A genome-wide corrected false discovery rate (FDR) of less than 0.05 was considered significant. Computations were performed on the Odyssey cluster supported by the FAS Science Division Research Computing Group at Harvard University.

Accession Numbers {#app1}
=================

RNA-seq data have been deposited to the Gene Expression Omnibus (accession number [GSE53212](ncbi-geo:GSE53212){#intref0015}).
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![*Nanog* Null MEFs Are Reprogrammed Using KSOM and Activate the Pluripotency Transcriptional Network\
(A) The number of iPSC colonies generated from *Nanog*^−/−^ MEFs with four factors (KSOM) or three factors (KSO). Colonies were scored at day 21 post transduction with reprogramming factors. Error bars represent the SD between two biological replicates.\
(B) Primary *Nanog*^−/−^ iPSC colony 17 days post transduction with KSOM. Scale bars represent 500 μm.\
(C) *Nanog*^−/−^ iPSCs growing on gelatin (top panels) or on irradiated feeder cells (bottom panels). Scale bars represent 500 μm.\
(D) *Nanog*^−/−^ iPSCs activate the endogenous *Nanog* locus. Cells were treated with 400 ng/ml G418 for 4 days, and representative images were taken at days 0 and 4. Scale bars represent 500 μm.\
See also [Figure S1](#app3){ref-type="sec"}.](gr1){#fig1}

![*Nanog* Null iPSCs Express Endogenous Pluripotency Genes\
(A) qPCR for expression of endogenous KSO. Levels are normalized to GAPDH and plotted relative to control V6.5 mESCs (=1). y axis shows the fold change in expression as determined by the comparative C~T~ method. qPCR was performed in duplicate. Error bars represent the SD between two biological replicates.\
(B) qPCR for expression of pluripotency-related genes. Levels are normalized to GAPDH and plotted relative to control V6.5 mESCs (=1). y axis shows the fold change in expression as determined by the comparative C~T~ method. qPCR was performed in duplicate. Error bars represent the SD between two biological replicates.\
See also [Figure S2](#app3){ref-type="sec"}.](gr2){#fig2}

![*Nanog* Null iPSCs Recapitulate the Global Transcriptome Profile of ESCs\
(A) Unsupervised hierarchical clustering of global gene expression obtained by RNA-seq. Biological replicates were analyzed for each sample, and the composite result is shown. piPSC, partially reprogrammed iPSC line B1. JS, Jenson Shannon.\
(B) The expression of selected pluripotency-associated factors, as well as early lineage and fibroblast markers, is shown. FPKM, fragments per kilobase of transcript per million fragments mapped. In the case of *Oct4* (*Pou5f1*) and *Sox2*, RNA-seq does not distinguish between endogenous and exogenous viral transcripts.\
(C) The overlap of genes significantly altered (FDR \<0.05) more than 2-fold between indicated pluripotent stem cells and MEFs is shown. Genes altered in either independent *Nanog*^−/−^ iPSC clone (G2 or G5) are included in the *Nanog*^−/−^ iPSC category.\
See also [Figure S3](#app3){ref-type="sec"}.](gr3){#fig3}

![*Nanog* Null iPSCs Are Pluripotent and Extensively Contribute to Chimeras\
(A) Representative images of brain, heart, lung, and liver from postnatal day 33 (P33) *Nanog*^−/−^ chimeras generated from injection of *Nanog*^−/−^ iPSC line 3.1 into WT blastocysts. Scale bars represent 5 mm.\
(B) Representative E12.5 chimeras generated from injection of *Nanog*^−/−^ iPSC line 3.1 into WT blastocysts. Scale bars represent 2 mm.\
(C) Four-week-old chimera generated from injection of *Nanog*^−/−^ iPSC line 3.1 into WT blastocysts.\
(D) Summary of chimera generation results from three and four factor lines (3.1, 3.2, G5). Numbers in boxes represent number of chimeras and number of embryos or animals recovered and total number of injected embryos. ND, not determined in this experiment. F, female.\
(E) Genotyping results of adult progeny (P90) from chimeric and C57BL/6 cross to determine germline transmission of *Nanog*^−/−^ iPSCs. neg, negative control GFP expression (C57BL/6 uncrossed animal).\
(F) Representative images of tissues from adult chimera progeny (P90) genotyped as positive (\#4) or negative (\#3) GFP transgene, as well as a chimera parent as a positive control. Scale bars represent 2 mm.\
See also [Figure S4](#app3){ref-type="sec"}.](gr4){#fig4}
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